BioHarvest Sciences (NASDAQ:BHST) Posts Earnings Results, Misses Estimates By $0.05 EPS

BioHarvest Sciences (NASDAQ:BHST) announced its quarterly earnings data on Monday. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.05), Zacks reports. The firm had revenue of $7.17 million for the quarter, compared to analysts’ expectations of $7.24 million.

BioHarvest Sciences Stock Up 4.8 %

BHST traded up $0.30 on Tuesday, reaching $6.49. 5,224 shares of the stock were exchanged, compared to its average volume of 8,004. BioHarvest Sciences has a fifty-two week low of $6.15 and a fifty-two week high of $7.38. The stock has a market capitalization of $106.60 million, a price-to-earnings ratio of -5.20 and a beta of 2.27. The firm’s 50-day moving average is $5.66.

Wall Street Analyst Weigh In

A number of analysts have issued reports on BHST shares. HC Wainwright initiated coverage on BioHarvest Sciences in a research note on Friday, December 6th. They issued a “buy” rating and a $14.00 price objective on the stock. Maxim Group began coverage on BioHarvest Sciences in a research note on Wednesday, December 18th. They set a “buy” rating and a $12.00 price target for the company.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.